Bosch and colleagues described that one-time AAV-FGF21 gene therapy in aged mice induced whole-body tissue-specific adaptations, including improved metabolic and mitochondrial function, restored proteostasis, and reduced adiposity, inflammation, fibrosis, and amyloidosis, thereby maintaining systemic cell fitness, preventing multi-organ age-related pathology, and prolonging health span.